Clinical Trial Update: Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease [Phase 3]

View source ↗

Summary

This is a Phase 3 extension study of inhaled treprostinil for fibrotic lung diseases, sponsored by United Therapeutics, with enrollment by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Interstitial Lung Disease
• Progressive Pulmonary Fibrosis

Drugs mentioned

• Tyvaso (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | Status: ENROLLING_BY_INVITATION